Truist assumed coverage of Arcus Biosciences (RCUS) with a Buy rating and a price target of $35, up from $30. The firm views the setup as “increasingly compelling,” with upside driven by casdatifan’s validated mechanism of action and emerging best-in-class profile in clear cell renal cell carcinoma, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS: